Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients
2018; Elsevier BV; Volume: 70; Issue: 1 Linguagem: Inglês
10.1016/j.jhep.2018.09.011
ISSN1600-0641
AutoresOlivier Marion, Sébastien Lhomme, Arnaud Del Bello, Florence Abravanel, Laure Esposito, Anne Laure Hébral, Laurence Lavayssière, Olivier Cointault, David Ribes, Jacques Izopet, Nassim Kamar,
Tópico(s)Liver Disease and Transplantation
ResumoHepatitis E virus genotype 3 (HEV3) and 4 (HEV4) can progress to chronic hepatitis in immunosuppressed patients.1 Ribavirin therapy has been shown to be efficient for treating chronic HEV infection in solid-organ-transplant recipients.2,3 Eighty percent of patients achieved a sustained virological response 24 weeks (SVR24) after ribavirin cessation.3 However, the optimal duration of ribavirin therapy is still undetermined. A rapid decrease of HEV RNA in blood under therapy was associated with SVR24.
Referência(s)